| |
| |
|
| Insider
Information: |
Sanna Bastiano |
| Relationship: |
Director |
| City: |
Boston |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
37,938 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$12,744,376 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
37,938 |
|
|
| Total
Value |
$12,744,376 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Cell & Genetic Th... |
2023-05-08 |
32,038 |
2021-02-03 |
0 |
Premium* |
|
|
Adicet Bio, Inc |
ACET |
Director |
2023-06-01 |
5,900 |
2023-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ACET |
Adicet Bio, Inc |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,900 |
5,900 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-08 |
4 |
AS |
$350.00 |
$997,500 |
D/D |
(2,850) |
32,038 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-05 |
4 |
AS |
$350.03 |
$147,713 |
D/D |
(422) |
34,888 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-03 |
4 |
AS |
$350.44 |
$975,418 |
D/D |
(2,781) |
35,310 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-02 |
4 |
AS |
$350.32 |
$568,768 |
D/D |
(1,622) |
38,091 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-04-12 |
4 |
AS |
$325.70 |
$2,472,164 |
D/D |
(7,567) |
39,713 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-04-04 |
4 |
AS |
$314.22 |
$164,854 |
D/D |
(522) |
47,280 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-03-16 |
4 |
AS |
$300.54 |
$825,423 |
D/D |
(2,746) |
49,268 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$1,147,806 |
D/D |
(3,970) |
52,014 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
55,984 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-14 |
4 |
AS |
$300.29 |
$655,161 |
D/D |
(2,181) |
59,734 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-13 |
4 |
AS |
$300.39 |
$33,944 |
D/D |
(113) |
61,915 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-13 |
4 |
D |
$298.26 |
$1,294,448 |
D/D |
(4,340) |
62,028 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-10 |
4 |
D |
$294.33 |
$265,486 |
D/D |
(902) |
66,368 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,272 |
67,270 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-01-31 |
4 |
AS |
$325.00 |
$34,450 |
D/D |
(106) |
37,998 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-11-02 |
4 |
AS |
$310.10 |
$100,045 |
D/D |
(320) |
38,104 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-11-01 |
4 |
D |
$312.84 |
$240,261 |
D/D |
(768) |
38,424 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-10-18 |
4 |
AS |
$300.02 |
$537,860 |
D/D |
(1,791) |
39,192 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-08-01 |
4 |
D |
$276.62 |
$211,891 |
D/D |
(766) |
40,983 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-05-16 |
4 |
AS |
$250.56 |
$11,377 |
D/D |
(45) |
41,749 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-05-02 |
4 |
AS |
$255.47 |
$82,930 |
D/D |
(320) |
41,696 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-29 |
4 |
D |
$276.17 |
$211,546 |
D/D |
(766) |
42,016 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-07 |
4 |
AS |
$275.71 |
$154,935 |
D/D |
(561) |
42,782 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-05 |
4 |
AS |
$275.23 |
$870,552 |
D/D |
(3,163) |
43,343 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
